Found 525 clinical trials
Flexible-Dose Trial in Early Parkinson's Disease (TemPo-2)
The purpose of this study is to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.
- 54 views
- 31 Jul, 2021
- 15 locations
Fixed-Dose Trial in Early Parkinson's Disease (TemPo-1)
The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early Parkinson's Disease.
- 84 views
- 12 Sep, 2021
- 36 locations
The Orchestra Study: An 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
The Orchestra Study (study number PD0053) is a clinical research study for people with early-stage Parkinson’s disease (<2 years). The aim of the study is to find out whether an investigational medication known as UCB0599 can slow the progression of Parkinson’s disease and whether it is efficacious and well tolerated (which means …
- 324 views
- 23 Jun, 2022
- 65 locations
Flexible-Dose Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TemPo-3)
The purpose of this study is to assess the effect of tavapadon on the change from baseline in total daily hours of "on" time without troublesome dyskinesia in L-Dopa-treated participants with Parkinson's Disease (PD) who are experiencing motor fluctuations.
- 48 views
- 31 Mar, 2022
- 46 locations
Spinal Cord Stimulation Therapy for Freezing of Gait in Parkinson's Syndrome Patients
therapeutic effect and safety of spinal cord stimulation for freezing of gait in patients with advanced Parkinson's disease and Parkinsonism-Plus syndrome.
- 0 views
- 28 Jan, 2021
- 1 location
Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy (RIVA-PSP)
Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease from the parkinsonian syndrome group. It represents 5 to 10% of all parkinsonian syndromes and affects 3,000 to 10,000
- 203 views
- 23 Feb, 2022
- 1 location
MotIoN aDaptive Deep Brain Stimulation for MSA (MINDS)
, and published evidence shows, that stimulation has effects on the autonomic nervous system. In patients undergoing therapeutic DBS for a particular subtype of Parkinsonism (Multiple System Atrophy
- 0 views
- 25 Mar, 2022
- 1 location
Video-oculography and Parkinson's Disease
This study aims to study, in patient with Parkinson's disease, mild to moderate stage (according to Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease, Postuma et al., 2015): the evolution of oculomotricity markers over time. the correlation between neurological evaluations (motor and non-motor scores), neuropsychological evaluations (cognitive disorders) and …
- 0 views
- 25 Jan, 2022
- 1 location
An Open-Label Phase 3 Study to Examine the Long-Term Safety Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
- 146 views
- 02 Apr, 2020
- 1 location
Phase 1/2a Clinical Trial of PR001A in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
The study PRV-PD101 is evaluating a potentially disease-modifying, single-dose gene therapy for patients with Parkinson’s disease with GBA1 mutations (PD-GBA). PD-GBA is driven by mutations in the gene GBA1. This gene contains the instructions for making the lysosomal enzyme beta-glucocerebrosidase, or GCase, which is needed for the disposal and recycling of glycolipids — a type …
- 24 views
- 13 May, 2022
- 4 locations